Gainers

• Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million.
• Mobile-health Network (NASDAQ:MNDR) shares increased by 35.71% to $0.77. The company's market cap stands at $4.1 million.
• ALPS Group (NASDAQ:ALPS) shares increased by 26.27% to $0.79. The company's market cap stands at $112.4 million.
• Catheter Precision (AMEX:VTAK) shares moved upwards by 17.39% to $1.08. The company's market cap stands at $2.3 million.
• Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 13.94% to $1.43. The company's market cap stands at $18.5 million.
• Exicure (NASDAQ:XCUR) shares increased by 8.79% to $2.97. The company's market cap stands at $17.4 million.

Losers

• Aditxt (NASDAQ:ADTX) shares declined by 8.2% to $0.04 during Tuesday's after-market session.
• Vivos Therapeutics (NASDAQ:VVOS) shares decreased by 7.53% to $0.43. The market value of their outstanding shares is at $5.5 million.
• Spyre Therapeutics (NASDAQ:SYRE) stock fell 7.53% to $89.75. The market value of their outstanding shares is at $8.6 billion.
• Silexion Therapeutics (NASDAQ:SLXN) shares decreased by 7.39% to $2.51. The market value of their outstanding shares is at $2.8 million.
• Galmed Pharmaceuticals (NASDAQ:GLMD) stock fell 6.68% to $0.53. The market value of their outstanding shares is at $4.3 million.
• Onconetix (NASDAQ:ONCO) stock declined by 5.61% to $1.01. The company's market cap stands at $3.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.